FIG. 1A



Placebo
1 mg
3 mg
6 mg
10 mg
Plasma SSAO activity (%baseline)
200
150
100
50
0
-50
4
168 (Day 7)

FIG. 1B



Placebo
1 mg
3 mg
6 mg
10 mg
Change from baseline (%)
20
0
-20
-40
-60
0
4
8
12
16
20
24
168
(Day 7)

FIG. 1C



MAO-A/B [IC50]
>800-fold margin
Dose
1 mg
3 mg
6 mg
10 mg
Formula 5 concentration (ng/mL)
Time Post-Dose (h)
20000
15000
10000
5000
20
15
10
5
0
0
2
4
6
8
10
12
14
16
18
20
22
24

FIG. 1D



Placebo
1 mg
3 mg
6 mg
10 mg
LLOQ
Methylamine (ng/mL)
50
40
30
20
10
0
Pre-dose
1
2
3
4
6
8
10
12
24
48
168
(Day 7)

FIG. 2A



G1 Health control
G3 Vehicle QD -2hr
G5 Compound of Formula 5 QD -2hr
G7 Oseltamivir BID -2hr
G9 Compound of Formula 5 + Oseltamivir QD+BID -2hr
G11 Compound of Formula 5 QD +36hr
G13 Oseltamivir BID +36hr
G15 Compound of Formula 5 + Oseltamivir QD+BID +36hr
Humane end point (-35%)
Body weight change(%)
(normalized by day 0)
10
0
-10
-20
-30
-40
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Days post-infection (d)

FIG. 2B



IFV titer, Log (plaque#/g lung)
9
8
7
6
5
4
3
2
1
0
LLOD=3
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2C



GM-CSF(pg/mL)
60
40
30
20
10
0
NS
NS
NS
NS
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2D



IFN-gamma (pg/mL)
2000
1500
1000
500
0
NS
NS
NS
NS
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2E



IL-1 beta (pg/mL)
20
15
10
5
0
NS
NS
NS
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2F



IL-12p70 (pg/mL)
100
80
60
40
20
0
***
NS
NS
***
***
***
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2G



IL-13(pg/mL)
20
15
10
5
0
NS
NS
***
NS
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2H



IL-18(pg/mL)
4000
3000
2000
1000
0
Health control
Vehicle -2hr
Compound of Formula S -2hr
Oseltamivir -2hr
Compound of Formula S + Oseltamivir -2hr
Compound of Formula S +36hr
Oseltamivir +36hr
Compound of Formula S + Oseltamivir +36hr

FIG. 2I



IL-2(pg/mL)
20
15
10
5
0
NS
NS
NS
NS
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2J



IL-4(pg/mL)
20
15
10
5
0
NS
NS
NS
NS
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2K



IL-5(pg/mL)
200
150
100
50
0
NS
NS
NS
NS
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2L



IL-6(pg/mL)
3000
2000
1000
0
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2M



TNF-alpha(pg/mL)
200
150
100
50
0
NS
NS
NS
Health control
Vehicle -2hr
Compound of Formula 5 -2hr
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Compound of Formula 5 +36hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr

FIG. 2N



1 - Health control
2 - Vehicle/Infection Control -2hr
3 - Compound of Formula 5 -2hr
4 - Oseltamivir -2hr
5 - Compound of Formula 5 + Oseltamivir -2hr
6 - Compound of Formula 5 +36hr
7 - Oseltamivir +36hr
8 - Compound of Formula 5 + Oseltamivir +36hr
Cells in BALF(cells/μL)
1500
1000
500
100
50
0
WBC
NEUT
LYM
MONO
1 2 3 4 5 6 7 8

FIG. 2O




Lung Histopathology Scoring by HE
15
10
5
0
****
****
Health control
Vehicle -2hr
Compound of Formula S -2hr
Oseltamivir -2hr
Compound of Formula S + Oseltamivir -2hr
Compound of Formula S +3Ghr
Oseltamivir +3Ghr
Compound of Formula S + Oseltamivir +3Ghr

FIG. 2P


Total fibrosis scores (Masson staining)
0
1
2
3
4
5
Health control
Oseltamivir -2hr
Compound of Formula 5 + Oseltamivir -2hr
Oseltamivir +36hr
Compound of Formula 5 + Oseltamivir +36hr
***
**